New therapeutic options for the treatment of Rheumatoid Arthritis;Neue Therapieentwicklungen in der Rheumatoiden Arthritis

Zeitschrift fur Rheumatologie

Volumn 60, Issue 5, 2001, Pages 326-332

  Lorenz, H M ^a   Kalden, J R ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; METHOTREXATE; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL; DRUG COMBINATION; HUMAN; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ENGLISH ABSTRACT; HUMAN; METHOTREXATE; TUMOR NECROSIS FACTOR;

EID: 0035488165     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930170032     Document Type: Article

References (33)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602
2. Kavanaugh A, Schaible T, DeWoody K, Marsters P, Dittrich K, Harriman G (1999) Long-term follow-up of patients treated with infliximab in clinical trials. Arthritis Rheum 42:S401
3. Moreland LM, Cohen SB, Baumgartner S, Schiff M, Tindall EA, Burge DJ (1999) Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis. Arthritis Rheum 42:S401
4. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
5. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287-1291
6. Davis MW, Feige U, Bendele AM, Martin SW, Edwards III CK (2000) Treatment of Rheumatoid Arthritis with PEGylated recombinant human soluble tumour necrosis factor type I: a clinical update. Ann Rheum Dis 59:i41-i43
7. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192:681-694
8. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243-1252
9. Skapenko A, Wendler J, Lipsky PE, Kalden JR, Schulze-Koops H (1999) Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol 163:491-499
10. van den Bosch F, Russell A, Chir B, Keystone EC, Moreland LW, St. Clair EW, Weinblatt M, Lipsky P, Bulpitt KJ, Kucharski K, Grint P, Wherry JC (1998) rHUIL-4 in subjects with rheumatoid arthritis: a phase I dose escalating savety study. Arthritis Rheum 41:556
11. Maini RN, Paulus H, Breedveld FC, Moreland LW, St. Clair EW, Russell AS, Charles P, Davies D, Grint P, Wherry JC, Feldmann M (1997) rHUIL-10 in subjects with rheumatoid arthritis: a phase I and cytokine response study. Arthritis Rheum 40:S224
12. Sigidin YA, Loukina GV, Skurkovich SV, Skurkovich BS (2000) Double-blind, placebo-controlled study of antibodies to Interferon-γ versus antibodies to TNFa in rheumatoid arthritis. Arthritis Rheum 43:S290
13. Kalunian KC, Davis J, Merrill IT, Petri M, Buyon I, Ginzler E, Furie R, Totoritis M, Wofsky D (2000) Treatment of Systemic Lupus Erythematosus by inhibition of T cell costimulation. Arthritis Rheum 43:5271
14. Morita Y, Yamamura M, Nishida K, Harada S, Okamoto H, Inoue H, Ohmoto Y, Modlin RL, Makino H (1998) Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 41:306-314
15. Thurkow EW, van der Heijden IM, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Tak PP (1997) Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 181:444-450
16. Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275-285
17. Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40:205-211
18. Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K (1997) Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121:540-546
19. Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KM (1998) Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 41:1639-1644
20. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G (2000) Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 60:1185-1195
21. Umezawa K, Ariga A, Matsumoto N (2000) Naturally occurring and synthetic inhibitors of NF-kappaB functions. Anticancer Drug Des 15:239-244
22. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest:135-142
23. Alexopoulou L, Pasparakis M, Kollias G (1997) A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 27:2588-2592
24. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593
25. Lorenz H-M, Kalden JR (1998) Biological drugs in rheumatoid arthritis: which ones could be used in combination? BioDrugs 9:303-324
26. Grünke M, Lorenz H-M, Schmidt M, Hieronymus T, Winkler S, Kalden JR, Manger B (1997) Combination therapy in rheumatoid arthritis (RA): TNFa antibodies inhibit mixed lymphocyte reaction in vitro synergistically with cyclosporine A or CD4 antibodies. Immunology Lett 56:42
27. Williams RO, Mauri C, Mason LJ, Marinova-Mutafchieva L, Ross SE, Feldmann M, Maini RN (1998) Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy. Arthritis Rheum 41:1806-1812
28. Williams RO, Mason LJ, Feldmann M, Maini RN (1994) Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91:2762-2766
29. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196-2204
30. Watt I, Cobby M (1996) Recombinant human IL-1 receptor antagonist (rhIL-1ra) reduces the rate of joint erosion in rheumatoid arthritis (RA). Arthritis Rheum 39:S123
31. Jorgensen C, Apparailly F, Couret I, Canovas F, Jacquet C, Sany J (1998) Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology 93:518-523
32. Müller-Ladner U, Roberts CR, Franklin BN, Gay RE, Robbins PD, Evans CH, Gay S (1997) Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol 158:3492-3498
33. O'Dell JR (1999) Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate. Clin Exp Rheumatol 17:S53-58